[1]张 伟.艾拉莫德联合塞来昔布治疗强直性脊柱炎的疗效[J].医学信息官方网站,2022,35(15):114-116.[doi:10.3969/j.issn.1006-1959.2022.15.026]
　ZHANG Wei.Efficacy of Iguratimod Combined with Celecoxib in the Treatment of Ankylosing Spondylitis[J].Medical Information,2022,35(15):114-116.[doi:10.3969/j.issn.1006-1959.2022.15.026]
点击复制

艾拉莫德联合塞来昔布治疗强直性脊柱炎的疗效()
分享到：

《医学信息》官方网站[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年15期
页码:
114-116
栏目:
论著
出版日期:
2022-08-01

文章信息/Info

Title:
Efficacy of Iguratimod Combined with Celecoxib in the Treatment of Ankylosing Spondylitis
文章编号:
1006-1959（2022）15-0114-03
作者:
张 伟
（天津市蓟州区人民医院药剂科，天津 301900）
Author(s):
ZHANG Wei
(Department of Pharmacy,Jizhou District People’s Hospital,Tianjin 301900,China)
关键词:
强直性脊柱炎; 艾拉莫德; 炎性因子; 骨代谢; 脊柱功能
Keywords:
Ankylosing spondylitis; Iguratimod; Inflammatory factors; Bone metabolism; Spinal function
分类号:
R593.23
DOI:
10.3969/j.issn.1006-1959.2022.15.026
文献标志码:
A
摘要:
目的 探讨艾拉莫德联合塞来昔布治疗强直性脊柱炎的疗效。方法 选取2019年7月-2020年12月我院就诊的69例强直性脊柱炎患者作为研究对象，采用随机数字表法分为对照组34例和观察组35例。对照组给予塞来昔布联合柳氮磺胺吡啶片治疗，观察组给予塞来昔布联合艾拉莫德治疗，比较两组临床疗效、骨代谢指标[超氧化物歧化酶（SOD）、Ⅰ型胶原交联羧基末端肽（CTX-Ⅰ）及骨钙素（BGP）]、炎性因子[红细胞沉降速率（ESR）、肿瘤坏死因子-α（TNF-α）及C反应蛋白（CRP）]水平、脊柱功能及不良反应发生情况。结果 观察组治疗总有效率为91.43%，高于对照组的76.47%（P＜0.05）；观察组治疗后SOD、CTX-Ⅰ、ESR、TNF-α、CRP水平及BASFI评分低于对照组，BGP水平高于对照组（P＜0.05）；观察组不良反应总发生率为5.71%，低于对照组的23.53%（P＜0.05）。结论 艾拉莫德联合塞来昔布治疗强直性脊柱炎的疗效确切，可促进骨代谢功能恢复，减轻脊柱炎性反应，改善脊柱功能，且不良反应发生率较低，安全性较高。
Abstract:
Objective To investigate the curative effect of iguratimod combined with celecoxib in the treatment of ankylosing spondylitis.Methods A total of 69 patients with ankylosing spondylitis admitted to our hospital from July 2019 to December 2020 were selected as the study subjects. They were divided into control group (34 cases) and observation group (35 cases) by random number table method. The control group was treated with celecoxib combined with sulfasalazine tablets, and the observation group was treated with celecoxib combined with iguratimod. The clinical efficacy, bone metabolism indexes [superoxide dismutase (SOD), type Ⅰ collagen cross-linked carboxy-terminal peptide (CTX-Ⅰ) and osteocalcin (BGP)], inflammatory factors [erythrocyte sedimentation rate (ESR), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP)], spinal function and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 91.43%, which was higher than 76.47% of the control group(P<0.05). After treatment, the levels of SOD, CTX-Ⅰ, ESR, TNF-α, CRP and BASFI scores in the observation group were lower than those in the control group, while the BGP level was higher than that in the control group (P<0.05). The total incidence of adverse reactions in the observation group was 5.71%, which was lower than 23.53% in the control group(P<0.05).Conclusion Iguratimod combined with celecoxib is effective in the treatment of ankylosing spondylitis, which can promote the recovery of bone metabolic function, reduce the inflammatory response of the spine, and improve the spinal function. The incidence of adverse reactions is low, and the safety is high.

参考文献/References:

[1]庞琳烜,郑朝晖,李治琴,等.艾拉莫德联合依那西普治疗强直性脊柱炎的疗效[J].热带医学杂志,2020,20(4):538-541.[2]袁芳芳,陈亚慧,林吉霞,等.艾拉莫德联合甲氨蝶呤治疗难治性强直性脊柱炎疗效及对患者血清SOD、CTX-Ⅰ水平影响[J].药物流行病学杂志,2020,29(3):163-165,205.[3]Wei JC,Chou MC,Huang JY,et al.The association between Candida infection and ankylosing spondylitis:a population-based matched cohort study[J].Curr Med Res Opin,2020,36(12):2063-2069.[4]曾惠琼,孔卫红,庄鹏,等.艾拉莫德治疗强直性脊柱炎疗效观察[J].海南医学,2016,27(1):118-120.[5]裘影影,汤郁,芮金兵,等.艾拉莫德治疗难治性强直性脊柱炎临床效果观察[J].江苏大学学报(医学版),2016,26(3):235-239.[6]王少纯,崔泽升.MRI骶髂关节评分评估五藤治尪汤结合西药治疗强直性脊柱炎的效果观察[J].中国CT和MRI杂志,2021,19(2):144-146.[7]Urkmez B,Keskin Y.Relationship between sleep quality and physical activity level in patients with ankylosing spondylitis[J].Mod Rheumatol,2020,30(6):1053-1059.[8]郑文标,黄皆和.老年强直性脊柱炎患者血清白细胞介素-28A、-28B、-29的水平及临床意义[J].中国老年学杂志,2020,40(1):129-131.[9]张宇,马莉,吴青青,等.强直性脊柱炎患者外周血CD4+CD25high CD127low、CD8+CD28-调节性T细胞水平变化及临床意义[J].中国免疫学杂志,2020,36(13):1625-1630.[10]杨西瑞,张磊,张旗,等.强直性脊柱炎患者甲襞微循环与BASDAI积分和血清VEGF水平的关系[J].山东医药,2020,60(22):69-72.[11]章良忠.老年强直性脊柱炎患者血清IL-18和IL-37水平及其与疗效和疾病活动度的关系[J].中国老年学杂志,2020,40(24):5245-5247.[12]孙美秀,韩善夯,甘可,等.强直性脊柱炎中医证型与骨质疏松相关性分析[J].中华中医药杂志,2020,35(6):3128-3130.[13]Wolfram JM,Zitt E,Bach CM.Surgical Treatment for Severe Fixed Hyperkyphosis in an Adult Patient Suffering From Ankylosing Spondylitis and Hereditary Hypophosphatemia With Vertebral Osteopetrosis[J].Clin Spine Surg,2020,33(8):307-313.[14]黄荣,胡启擂,李宏,等.血清铁蛋白在强直性脊柱炎诊治中的价值[J].中国卫生检验杂志,2020,30(11):1370-1372.[15]许百洁,莫守崎,薛晓倩,等.艾拉莫德治疗强直性脊柱炎的疗效和安全性研究[J].新医学,2019,50(12):915-918.[16]于守杰,贾倩.艾拉莫德联合依那西普治疗难治性类风湿关节炎的疗效[J].医学信息,2020,33(9):140-141.[17]李连菊,王京旭.艾拉莫德分别联合甲氨蝶呤和双醋瑞因对难治性类风湿关节炎患者相关指标的影响比较[J].中国药房,2017,28(6):769-772.[18]黎声飞.艾拉莫德与双醋瑞因对难治性类风湿关节炎患者的疗效及其对炎症因子和超氧化歧化酶等指标水平的影响[J].抗感染药学,2018,15(1):153-155.

相似文献/References:

[1]朱晓波,常 泰.强直性脊柱炎髋关节受累磁共振横断面扫描与 冠状面扫描的对比分析[J].医学信息官方网站,2018,31(16):186.[doi:10.3969/j.issn.1006-1959.2018.16.060]
　ZHU Xiao-bo,CHANG Tai.Comparative Analysis of Magnetic Resonance Cross-sectional Scan and Coronal Scan in Hip Joint of Ankylosing Spondylitis[J].Medical Information,2018,31(15):186.[doi:10.3969/j.issn.1006-1959.2018.16.060]
[2]刘军莲,戴 娜,杨 迎,等.全脊柱MRI对强直性脊柱炎急性炎症的诊断价值[J].医学信息官方网站,2019,32(16):167.[doi:10.3969/j.issn.1006-1959.2019.16.057]
　LIU Jun-lian,DAI Na,YANG Ying,et al.Diagnostic Value of Total Spine MRI in Acute Inflammation of Ankylosing Spondylitis[J].Medical Information,2019,32(15):167.[doi:10.3969/j.issn.1006-1959.2019.16.057]
[3]翁於欢,王璐颖,郑 勇,等.强直性脊柱炎中医证候分布研究[J].医学信息官方网站,2020,33(01):151.[doi:10.3969/j.issn.1006-1959.2020.01.049]
　WENG Yu-huan,WANG Lu-ying,ZHENG Yong,et al.Study on TCM Syndrome Distribution of Ankylosing Spondylitis[J].Medical Information,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.01.049]
[4]于守杰,贾 倩.艾拉莫德联合依那西普治疗难治性类风湿关节炎的疗效[J].医学信息官方网站,2020,33(09):140.[doi:10.3969/j.issn.1006-1959.2020.09.045]
　YU Shou-jie,JIA Qian.Effect of Iguratimod with Etanercept in the Treatment of Refractory Rheumatoid Arthritis[J].Medical Information,2020,33(15):140.[doi:10.3969/j.issn.1006-1959.2020.09.045]
[5]陈王曼琍,施春香.Orem自理理论护理对中西医结合治疗强直性脊柱炎的疗效研究[J].医学信息官方网站,2020,33(11):182.[doi:10.3969/j.issn.1006-1959.2020.11.060]
　CHEN Man-li,SHI Chun-xiang.Study on the Curative Effect of Orem Self-care Theory Nursing Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western Medicine[J].Medical Information,2020,33(15):182.[doi:10.3969/j.issn.1006-1959.2020.11.060]
[6]黄少辉,李 渊,李淑婧,等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白逐步减量维持治疗强直性脊柱炎的效果[J].医学信息官方网站,2021,34(02):152.[doi:10.3969/j.issn.1006-1959.2021.02.042]
　HUANG Shao-hui,LI Yuan,LI Shu-jing,et al.Effect of Recombinant Human Type II Tumor Necrosis Factor Receptor-antibody Fusion Protein Reduction on the Treatment of Ankylosing Spondylitis[J].Medical Information,2021,34(15):152.[doi:10.3969/j.issn.1006-1959.2021.02.042]
[7]薛三宝.MRI诊断强直性脊柱炎骶髂关节病变的影像学价值[J].医学信息官方网站,2022,35(22):142.[doi:10.3969/j.issn.1006-1959.2022.22.034]
　XUE San-bao.Imaging Value of MRI in Diagnosis of Sacroiliac Joint Lesions in Ankylosing Spondylitis[J].Medical Information,2022,35(15):142.[doi:10.3969/j.issn.1006-1959.2022.22.034]
[8]叶 路.益赛普联合柳氮磺吡啶治疗强直性脊柱炎的疗效及对血清炎性因子的影响[J].医学信息官方网站,2024,37(16):108.[doi:10.3969/j.issn.1006-1959.2024.16.024]
　YE Lu.Efficacy of YISAIPU Combined with Sulfasalazine in the Treatment of Ankylosing Spondylitisand its Effect on Serum Inflammatory Factors[J].Medical Information,2024,37(15):108.[doi:10.3969/j.issn.1006-1959.2024.16.024]

更新日期/Last Update: 1900-01-01